Symbols / APVO Stock $4.63 -1.07%
APVO (Stock) Chart
About
Asset: Stock
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 7.23M |
| Enterprise Value | -11.94M | Income | -27.95M | Sales | — |
| Book/sh | 22.67 | Cash/sh | 22.50 | Dividend Yield | — |
| Payout | 0.00% | Employees | 37 | IPO | — |
| P/E | 0.00 | Forward P/E | -0.16 | PEG | — |
| P/S | — | P/B | 0.20 | P/C | — |
| EV/EBITDA | 0.45 | EV/Sales | — | Quick Ratio | 3.75 |
| Current Ratio | 4.03 | Debt/Eq | 27.54 | LT Debt/Eq | — |
| EPS (ttm) | 7758.20 | EPS next Y | -28.87 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-06 16:00 | ROA | -79.19% |
| ROE | -242.74% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 1.56M |
| Shs Float | 935.44K | Short Float | 11.71% | Short Ratio | 2.66 |
| Short Interest | — | 52W High | 1299.60 | 52W Low | 3.95 |
| Beta | 1.43 | Avg Volume | 194.82K | Volume | 29.04K |
| Target Price | $21.00 | Recom | Strong_buy | Prev Close | $4.68 |
| Price | $4.63 | Change | -1.07% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$21.00
Mean price target
2. Current target
$4.63
Latest analyst target
3. DCF / Fair value
$-185.94
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.63
Low
$21.00
High
$21.00
Mean
$21.00
- Leukemia trial: 86% of older patients benefit, no cytokine release syndrome - Stock Titan ue, 10 Mar 2026 12
- Aptevo Therapeutics (APVO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance Wed, 19 Nov 2025 08
- $APVO stock is down 27% today. Here's what we see in our data. - Quiver Quantitative Fri, 26 Dec 2025 08
- Should I buy Aptevo Therapeutics (APVO) - Zacks Investment Research Wed, 19 Nov 2025 08
- Aptevo Therapeutics stock tumbles despite positive trial data - Investing.com ue, 10 Mar 2026 12
- Aptevo Therapeutics Shareholders Approve Expanded Equity Financing Capacity - The Globe and Mail Fri, 20 Feb 2026 08
- Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split - ACCESS Newswire Fri, 26 Dec 2025 08
- Aptevo Therapeutics (NASDAQ: APVO) shows 100% CRS-free safety, 87% CR/CRi in AML - Stock Titan ue, 09 Dec 2025 08
- Biotech firm turns every 18 shares into 1 in year-end stock move - Stock Titan Fri, 26 Dec 2025 08
- Insider Purchase: Director at $APVO Buys 13,513 Shares - Quiver Quantitative Wed, 12 Nov 2025 08
- Biotech lines up $60M to keep next-wave cancer drugs moving to 2029 - Stock Titan Fri, 09 Jan 2026 08
- Aptevo (NASDAQ: APVO) extends cash runway to 4Q26 on $18.7M raise and business update - Stock Titan hu, 06 Nov 2025 08
- APVO - Aptevo Therapeutics Inc Latest Stock News & Market Updates - Stock Titan Sun, 22 Feb 2026 17
- Cancer drug developer Aptevo hands CEO role to operations chief - Stock Titan ue, 03 Feb 2026 08
- Aptevo Therapeutics (APVO) reports 86% benefit, no CRS in mipletamig AML data - Stock Titan ue, 10 Mar 2026 21
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 13513 | 20134.0 | — | Purchase at price 1.49 per share. | GRANT GRADY III | Director | — | 2025-11-10 00:00:00 | D |
| 1 | 1 | nan | — | — | HARSANYI ZSOLT | Director | — | 2025-07-17 00:00:00 | D |
| 2 | 3 | nan | — | — | TAYLOR DAPHNE L | Chief Financial Officer | — | 2025-07-17 00:00:00 | D |
| 3 | 10 | nan | — | — | WHITE MARVIN L | Chief Executive Officer | — | 2025-07-17 00:00:00 | D |
| 4 | 1 | nan | — | — | NIEDERHUBER JOHN | Director | — | 2025-07-17 00:00:00 | D |
| 5 | 5 | nan | — | — | LAMOTHE JEFFREY G | Chief Operating Officer | — | 2025-07-17 00:00:00 | D |
| 6 | 1 | nan | — | — | GRANT GRADY III | Director | — | 2025-07-17 00:00:00 | D |
| 7 | 1 | nan | — | — | KUNZ BARBARA LOPEZ | Director | — | 2025-07-17 00:00:00 | D |
| 8 | 1 | nan | — | — | ABDUN-NABI DANIEL J | Director | — | 2025-07-17 00:00:00 | D |
| 9 | 3 | nan | — | — | KWON SOYOUNG | General Counsel | — | 2025-07-17 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -24.25M | -37.96M | -27.74M | -20.26M |
| TotalUnusualItems | 0.00 | 9.65M | 0.00 | 0.00 |
| TotalUnusualItemsExcludingGoodwill | 0.00 | 9.65M | 0.00 | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -24.13M | -18.65M | 7.01M | -29.41M |
| ReconciledDepreciation | 352.00K | 567.00K | 901.00K | 1.14M |
| EBITDA | -24.25M | -28.31M | -27.74M | -20.26M |
| EBIT | -24.60M | -28.88M | -28.64M | -21.40M |
| NormalizedIncome | -24.13M | -28.30M | 7.01M | -29.41M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -24.13M | -17.41M | 8.03M | -28.46M |
| TotalExpenses | 24.60M | 28.88M | 31.75M | 33.69M |
| TotalOperatingIncomeAsReported | -24.60M | -28.88M | -28.64M | -21.40M |
| DilutedAverageShares | 4.05K | 33.00 | 11.00 | 8.00 |
| BasicAverageShares | 4.05K | 33.00 | 11.00 | 8.00 |
| DilutedEPS | -5.96K | -527.61K | 729.73K | -3.56M |
| BasicEPS | -5.96K | -527.61K | 729.73K | -3.56M |
| DilutedNIAvailtoComStockholders | -24.13M | -17.41M | 8.03M | -28.46M |
| NetIncomeCommonStockholders | -24.13M | -17.41M | 8.03M | -28.46M |
| NetIncome | -24.13M | -17.41M | 8.03M | -28.46M |
| NetIncomeIncludingNoncontrollingInterests | -24.13M | -17.41M | 8.03M | -28.46M |
| NetIncomeDiscontinuousOperations | 0.00 | 1.24M | 1.01M | 951.00K |
| NetIncomeContinuousOperations | -24.13M | -18.65M | 7.01M | -29.41M |
| PretaxIncome | -24.13M | -18.65M | 7.01M | -29.41M |
| OtherIncomeExpense | 472.00K | 10.23M | 35.66M | -8.01M |
| OtherNonOperatingIncomeExpenses | 472.00K | 578.00K | 35.66M | -8.01M |
| SpecialIncomeCharges | 0.00 | 9.65M | 0.00 | 0.00 |
| GainOnSaleOfPPE | 0.00 | 9.65M | 0.00 | |
| OtherSpecialCharges | -37.18M | |||
| OperatingIncome | -24.60M | -28.88M | -28.64M | -21.40M |
| OperatingExpense | 24.60M | 28.88M | 31.75M | 33.69M |
| ResearchAndDevelopment | 14.38M | 17.11M | 17.88M | 18.99M |
| SellingGeneralAndAdministration | 10.22M | 11.77M | 13.87M | 14.70M |
| GeneralAndAdministrativeExpense | 10.22M | 11.77M | 13.87M | 14.70M |
| OtherGandA | 10.22M | 11.77M | 13.87M | 14.70M |
| TotalRevenue | 0.00 | 0.00 | 3.11M | 12.29M |
| OperatingRevenue | 0.00 | 0.00 | 3.11M | 12.29M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 4.05K | 33.00 | 11.00 | 8.00 |
| ShareIssued | 4.05K | 33.00 | 11.00 | 8.00 |
| TotalDebt | 4.63M | 5.40M | 9.54M | 16.71M |
| TangibleBookValue | 4.75M | 12.22M | 17.97M | 1.22M |
| InvestedCapital | 4.75M | 12.22M | 21.43M | 16.59M |
| WorkingCapital | 4.45M | 11.84M | 18.74M | 17.81M |
| NetTangibleAssets | 4.75M | 12.22M | 17.97M | 1.22M |
| CapitalLeaseObligations | 4.63M | 5.40M | 6.08M | 1.34M |
| CommonStockEquity | 4.75M | 12.22M | 17.97M | 1.22M |
| TotalCapitalization | 4.75M | 12.22M | 19.43M | 4.92M |
| TotalEquityGrossMinorityInterest | 4.75M | 12.22M | 17.97M | 1.22M |
| StockholdersEquity | 4.75M | 12.22M | 17.97M | 1.22M |
| RetainedEarnings | -247.58M | -223.45M | -206.04M | -214.06M |
| AdditionalPaidInCapital | 252.25M | 235.61M | 223.96M | 215.23M |
| CapitalStock | 84.00K | 61.00K | 48.00K | 47.00K |
| CommonStock | 84.00K | 61.00K | 48.00K | 47.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 10.84M | 12.62M | 16.24M | 55.38M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 4.63M | 5.40M | 7.54M | 20.63M |
| OtherNonCurrentLiabilities | 15.58M | |||
| LongTermDebtAndCapitalLeaseObligation | 4.63M | 5.40M | 7.54M | 5.05M |
| LongTermCapitalLeaseObligation | 4.63M | 5.40M | 6.08M | 1.34M |
| LongTermDebt | 1.46M | 3.71M | ||
| CurrentLiabilities | 6.21M | 7.22M | 8.71M | 34.76M |
| OtherCurrentLiabilities | 1.30M | 1.14M | 1.10M | 17.55M |
| CurrentDebtAndCapitalLeaseObligation | 2.00M | 11.67M | ||
| CurrentDebt | 2.00M | 11.67M | ||
| OtherCurrentBorrowings | 2.00M | 11.67M | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.86M | 2.10M | 2.10M | 2.08M |
| PayablesAndAccruedExpenses | 3.05M | 3.98M | 3.50M | 3.46M |
| TotalAssets | 15.59M | 24.84M | 34.22M | 56.60M |
| TotalNonCurrentAssets | 4.93M | 5.78M | 6.76M | 4.03M |
| OtherNonCurrentAssets | 68.00K | |||
| NetPPE | 4.93M | 5.78M | 6.76M | 3.96M |
| AccumulatedDepreciation | -13.95M | -13.59M | -13.03M | -12.28M |
| GrossPPE | 18.88M | 19.37M | 19.79M | 16.24M |
| Leases | 2.23M | 2.23M | 2.23M | 2.23M |
| OtherProperties | 7.00K | |||
| MachineryFurnitureEquipment | 12.26M | 12.26M | 12.26M | 12.43M |
| BuildingsAndImprovements | 4.39M | 4.88M | 5.30M | 1.58M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 10.66M | 19.07M | 27.45M | 52.57M |
| OtherCurrentAssets | 256.00K | 689.00K | 744.00K | 780.00K |
| RestrictedCash | 0.00 | 1.26M | ||
| PrepaidAssets | 1.69M | 1.47M | 1.57M | 1.82M |
| Receivables | 0.00 | 2.50M | 3.66M | |
| OtherReceivables | 2.50M | 3.66M | ||
| CashCashEquivalentsAndShortTermInvestments | 8.71M | 16.90M | 22.64M | 45.04M |
| CashAndCashEquivalents | 8.71M | 16.90M | 22.64M | 45.04M |
| CashEquivalents | 7.53M | 13.17M | 21.57M | 41.20M |
| CashFinancial | 1.18M | 3.73M | 1.07M | 3.84M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -23.79M | -11.73M | -21.05M | -22.39M |
| RepaymentOfDebt | 0.00 | -3.47M | -12.27M | -10.55M |
| IssuanceOfCapitalStock | 10.04M | 6.43M | 6.93M | 10.23M |
| CapitalExpenditure | -29.00K | -713.00K | ||
| EndCashPosition | 8.71M | 16.90M | 22.64M | 46.30M |
| BeginningCashPosition | 16.90M | 22.64M | 46.30M | 42.53M |
| ChangesInCash | -8.19M | -5.73M | -23.67M | 3.77M |
| FinancingCashFlow | 15.60M | 6.00M | -2.62M | 26.16M |
| CashFlowFromContinuingFinancingActivities | 15.60M | 6.00M | -2.62M | 26.16M |
| NetOtherFinancingCharges | -4.00K | -10.00K | 2.72M | 25.27M |
| ProceedsFromStockOptionExercised | 5.56M | 3.05M | 0.00 | 1.21M |
| NetCommonStockIssuance | 10.04M | 6.43M | 6.93M | 10.23M |
| CommonStockIssuance | 10.04M | 6.43M | 6.93M | 10.23M |
| NetIssuancePaymentsOfDebt | 0.00 | -3.47M | -12.27M | -10.55M |
| NetLongTermDebtIssuance | 0.00 | -3.47M | -12.27M | -10.55M |
| LongTermDebtPayments | 0.00 | -3.47M | -12.27M | -10.55M |
| InvestingCashFlow | 0.00 | 0.00 | -29.00K | -713.00K |
| CashFlowFromContinuingInvestingActivities | 0.00 | -29.00K | -713.00K | |
| NetBusinessPurchaseAndSale | 0.00 | |||
| SaleOfBusiness | 0.00 | |||
| NetPPEPurchaseAndSale | 0.00 | -29.00K | -713.00K | |
| PurchaseOfPPE | 0.00 | -29.00K | -713.00K | |
| OperatingCashFlow | -23.79M | -11.73M | -21.02M | -21.68M |
| CashFlowFromContinuingOperatingActivities | -23.79M | -11.73M | -21.02M | -21.68M |
| ChangeInWorkingCapital | -1.08M | 2.91M | 2.14M | -2.65M |
| ChangeInOtherCurrentLiabilities | -768.00K | -682.00K | 366.00K | -1.02M |
| ChangeInOtherCurrentAssets | 492.00K | 422.00K | 653.00K | 1.14M |
| ChangeInPayablesAndAccruedExpense | -1.02M | 518.00K | -394.00K | -1.92M |
| ChangeInPayable | -1.02M | 518.00K | -394.00K | -1.92M |
| ChangeInAccountPayable | -1.02M | 518.00K | -394.00K | -1.92M |
| ChangeInPrepaidAssets | 217.00K | 153.00K | 355.00K | 436.00K |
| ChangeInReceivables | 0.00 | 2.50M | 1.16M | -1.29M |
| OtherNonCashItems | 10.00K | -33.94M | 6.64M | |
| StockBasedCompensation | 1.07M | 2.19M | 1.80M | 1.64M |
| DepreciationAmortizationDepletion | 352.00K | 567.00K | 901.00K | 1.14M |
| DepreciationAndAmortization | 352.00K | 567.00K | 901.00K | 1.14M |
| OperatingGainsLosses | 47.00K | 4.00K | ||
| GainLossOnSaleOfPPE | 0.00 | 47.00K | 4.00K | |
| GainLossOnSaleOfBusiness | 0.00 | |||
| NetIncomeFromContinuingOperations | -24.13M | -17.41M | 8.03M | -28.46M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for APVO
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|